Details of the Drug

General Information of Drug (ID: DMG592Q)

Drug Name
Solifenacin
Synonyms
Vesicare; Vesikur; Solifenacin succinate; Solifenacin succinate [USAN]; YM 905; Solifenacin (INN); Solifenacin [INN:BAN]; Vesicare (TN); YM-53705; YM-67905; YM-905; Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1)
Indication
Disease Entry ICD 11 Status REF
Overactive bladder GC50.0 Approved [1], [2]
Therapeutic Class
Antispasmodics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 362.5
Topological Polar Surface Area (xlogp) 4
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-1.5 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 23% [3]
Clearance
The renal clearance of drug is 0.67-1.51 L/h [5]
Elimination
69.2 +/- 7.8% of a radiolabelled dose is recovered in the urine, 22.5 +/- 3.3% was recovered in feces, and 0.4 +/- 7.8% was recovered in exhaled air [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 33 - 85 hours [5]
Metabolism
The drug is metabolized via the cytochrome P450 [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.29728 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [7]
Vd
The volume of distribution (Vd) of drug is 600 L [5]
Chemical Identifiers
Formula
C23H26N2O2
IUPAC Name
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
Canonical SMILES
C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5
InChI
InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1
InChIKey
FBOUYBDGKBSUES-VXKWHMMOSA-N
Cross-matching ID
PubChem CID
154059
ChEBI ID
CHEBI:135530
CAS Number
242478-37-1
DrugBank ID
DB01591
TTD ID
D0L4YD
INTEDE ID
DR1497

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M3 (CHRM3) TTQ13Z5 ACM3_HUMAN Antagonist [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Overactive bladder
ICD Disease Classification GC50.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Muscarinic acetylcholine receptor M3 (CHRM3) DTT CHRM3 4.61E-07 -0.59 -0.73
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Solifenacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Solifenacin and Ivosidenib. Acute myeloid leukaemia [2A60] [37]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Midostaurin. Acute myeloid leukaemia [2A60] [38]
Arn-509 DMT81LZ Moderate Increased metabolism of Solifenacin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [39]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Gilteritinib. Acute myeloid leukaemia [2A60] [40]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Solifenacin and Oliceridine. Acute pain [MG31] [41]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Solifenacin and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [42]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Solifenacin and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [42]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Solifenacin and Ivabradine. Angina pectoris [BA40] [43]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Solifenacin and Dronedarone. Angina pectoris [BA40] [38]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Solifenacin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [44]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Solifenacin and Levalbuterol. Asthma [CA23] [45]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Solifenacin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [46]
Troleandomycin DMUZNIG Major Decreased metabolism of Solifenacin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [47]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Retigabine. Behcet disease [4A62] [38]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Solifenacin and Cariprazine. Bipolar disorder [6A60] [48]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Solifenacin caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [39]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Eribulin. Breast cancer [2C60-2C6Y] [38]
Tucatinib DMBESUA Major Decreased metabolism of Solifenacin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Palbociclib DMD7L94 Moderate Decreased metabolism of Solifenacin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [39]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Solifenacin when combined with Acetylcholine. Cataract [9B10] [49]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Solifenacin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [50]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Solifenacin and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [51]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Solifenacin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [52]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Solifenacin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [45]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Solifenacin and Revefenacin. Chronic obstructive pulmonary disease [CA22] [51]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Solifenacin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [52]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Probucol. Coronary atherosclerosis [BA80] [38]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Solifenacin and Pasireotide. Cushing syndrome [5A70] [38]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Osilodrostat. Cushing syndrome [5A70] [43]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Solifenacin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [39]
MK-8228 DMOB58Q Moderate Decreased metabolism of Solifenacin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [39]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Solifenacin and OPC-34712. Depression [6A70-6A7Z] [48]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Solifenacin and Mepenzolate. Digestive system disease [DE2Z] [48]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [38]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Deutetrabenazine. Dystonic disorder [8A02] [53]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Ingrezza. Dystonic disorder [8A02] [54]
Cenobamate DMGOVHA Moderate Increased metabolism of Solifenacin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Stiripentol DMMSDOY Moderate Decreased metabolism of Solifenacin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Tazemetostat DMWP1BH Moderate Increased metabolism of Solifenacin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [39]
Boceprevir DMBSHMF Major Decreased metabolism of Solifenacin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [47]
Telaprevir DMMRV29 Major Decreased metabolism of Solifenacin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [47]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [55]
Cobicistat DM6L4H2 Major Decreased metabolism of Solifenacin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [47]
Etravirine DMGV8QU Moderate Increased metabolism of Solifenacin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [38]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Solifenacin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [39]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Solifenacin and Belladonna. Infectious gastroenteritis/colitis [1A40] [48]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Solifenacin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [39]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Solifenacin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [39]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Solifenacin and ITI-007. Insomnia [7A00-7A0Z] [48]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Solifenacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [43]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Solifenacin and Phenolphthalein. Irritable bowel syndrome [DD91] [38]
R0-93877 DMM4U9G Moderate Antagonize the effect of Solifenacin when combined with R0-93877. Irritable bowel syndrome [DD91] [57]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Solifenacin and Crizotinib. Lung cancer [2C25] [58]
Brigatinib DM7W94S Moderate Increased metabolism of Solifenacin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [59]
Ceritinib DMB920Z Major Decreased metabolism of Solifenacin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [47]
PF-06463922 DMKM7EW Moderate Increased metabolism of Solifenacin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [39]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Solifenacin and Osimertinib. Lung cancer [2C25] [60]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Solifenacin and Selpercatinib. Lung cancer [2C25] [43]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Solifenacin and Lumefantrine. Malaria [1F40-1F45] [47]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Solifenacin and Hydroxychloroquine. Malaria [1F40-1F45] [61]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [43]
Idelalisib DM602WT Major Decreased metabolism of Solifenacin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [47]
IPI-145 DMWA24P Moderate Decreased metabolism of Solifenacin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [39]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Solifenacin and Vemurafenib. Melanoma [2C30] [38]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Solifenacin and LGX818. Melanoma [2C30] [62]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Solifenacin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [39]
Exjade DMHPRWG Moderate Decreased metabolism of Solifenacin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [63]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Solifenacin and Panobinostat. Multiple myeloma [2A83] [64]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Solifenacin and Siponimod. Multiple sclerosis [8A40] [47]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Solifenacin and Fingolimod. Multiple sclerosis [8A40] [38]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Solifenacin and Ozanimod. Multiple sclerosis [8A40] [65]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Romidepsin. Mycosis fungoides [2B01] [38]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Solifenacin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [39]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Solifenacin and Nilotinib. Myeloproliferative neoplasm [2A20] [38]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Solifenacin and Phenindamine. Nasopharyngitis [CA00] [48]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Lofexidine. Opioid use disorder [6C43] [38]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Rucaparib. Ovarian cancer [2C73] [38]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Triclabendazole. Parasitic worm infestation [1F90] [38]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Pimavanserin. Parkinsonism [8A00] [66]
Abametapir DM2RX0I Moderate Decreased metabolism of Solifenacin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [67]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Solifenacin and Methylscopolamine. Peptic ulcer [DA61] [48]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Solifenacin and Macimorelin. Pituitary gland disorder [5A60-5A61] [68]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Solifenacin and Lefamulin. Pneumonia [CA40] [69]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Solifenacin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [47]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Degarelix. Prostate cancer [2C82] [43]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Solifenacin and ABIRATERONE. Prostate cancer [2C82] [43]
Enzalutamide DMGL19D Moderate Increased metabolism of Solifenacin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [39]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Relugolix. Prostate cancer [2C82] [43]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Solifenacin and Iloperidone. Schizophrenia [6A20] [38]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Solifenacin and Molindone. Schizophrenia [6A20] [48]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Solifenacin and Thiothixene. Schizophrenia [6A20] [48]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Solifenacin and Amisulpride. Schizophrenia [6A20] [70]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Asenapine. Schizophrenia [6A20] [38]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Solifenacin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [43]
Larotrectinib DM26CQR Moderate Decreased metabolism of Solifenacin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [39]
Armodafinil DMGB035 Minor Increased metabolism of Solifenacin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [71]
LEE011 DMMX75K Major Decreased metabolism of Solifenacin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [38]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [43]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [38]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Solifenacin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [72]
Brilinta DMBR01X Moderate Decreased metabolism of Solifenacin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [39]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Solifenacin and Lenvatinib. Thyroid cancer [2D10] [38]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Solifenacin and Cabozantinib. Thyroid cancer [2D10] [43]
Elagolix DMB2C0E Moderate Increased metabolism of Solifenacin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [39]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Solifenacin and Acrivastine. Vasomotor/allergic rhinitis [CA08] [48]
⏷ Show the Full List of 106 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7483).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021518.
3 Latini R, Tognoni G, Kates RE: Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984 Mar-Apr;9(2):136-56. doi: 10.2165/00003088-198409020-00002.
4 BDDCS applied to over 900 drugs
5 Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302. doi: 10.2165/00003088-200948050-00001.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
9 Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
10 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
20 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
21 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
22 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
23 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
24 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
25 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
26 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
27 Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
28 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
29 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
30 Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
31 M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
32 Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
33 Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
34 Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
35 Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.
36 Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors. J Biol Chem. 1993 Oct 25;268(30):22436-43.
37 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
38 Canadian Pharmacists Association.
39 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
40 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
41 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
42 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
43 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
44 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
45 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
46 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
47 Cerner Multum, Inc. "Australian Product Information.".
48 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
49 Multum Information Services, Inc. Expert Review Panel.
50 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
51 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
52 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
53 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
54 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
55 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
56 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
57 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
58 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
59 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
60 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
61 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
62 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
63 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
64 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
65 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
66 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
67 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
68 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
69 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
70 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
71 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
72 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.